Brickell Biotech, Inc.

0.7600-0.0300-3.80%Vol 618.52K1Y Perf -4.94%
Sep 15th, 2021 16:00 DELAYED
BID0.7601 ASK0.7696
Open0.7900 Previous Close0.7900
Pre-Market- After-Market-
 - -%  - -
Target Price
5.00 
Analyst Rating
— 0.00
Potential %
557.90 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★+     48.21
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★+     49.49
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
23.82 
Earnings Rating
Market Cap65.30M 
Earnings Date
12th Aug 2021
Alpha-0.04 Standard Deviation0.21
Beta0.20 

Today's Price Range

0.76000.7950

52W Range

0.46601.70

5 Year PE Ratio Range

-2.30-1.60

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
-2.19%
1 Month
20.18%
3 Months
-11.55%
6 Months
-33.33%
1 Year
-4.94%
3 Years
-92.19%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
BBI0.7600-0.0300-3.80
AAPL149.030.91000.61
GOOG2 904.1236.00001.26
MSFT304.825.03001.68
XOM56.421.84003.37
WFC46.640.59001.28
JNJ165.420.62000.38
FB373.92-2.6100-0.69
GE102.161.78001.77
JPM158.161.09000.69
Financial StrengthValueIndustryS&P 500US Markets
3.70
4.30
0.00
0.00
-496.60
Leverage Ratio 1.30
ProfitabilityValueIndustryS&P 500US Markets
-
-9 430.60
-9 427.00
-521.40
-
RevenueValueIndustryS&P 500US Markets
337.00K
0.00
-40.63
-47.74
Earnings HistoryEstimateReportedSurprise %
Q02 2021-0.11-0.16-45.45
Q01 2021-0.12-0.15-25.00
Q04 2020-0.08-0.15-87.50
Q03 2020-0.17-0.1511.76
Q02 2020--0.43-
Q01 2020--0.45-
Q04 2019--1.38-
Q03 2019--2.27-
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-0.11
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume618.52K
Shares Outstanding85.92M
Shares Float83.87M
Trades Count1.01K
Dollar Volume2.76M
Avg. Volume2.10M
Avg. Weekly Volume733.61K
Avg. Monthly Volume794.78K
Avg. Quarterly Volume1.19M

Brickell Biotech, Inc. (NASDAQ: BBI) stock closed at 0.76 per share at the end of the most recent trading day (a -3.8% change compared to the prior day closing price) with a volume of 655.11K shares and market capitalization of 65.30M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 15 people. Brickell Biotech, Inc. CEO is Robert Busard Brown.

The one-year performance of Brickell Biotech, Inc. stock is -4.94%, while year-to-date (YTD) performance is -2.63%. BBI stock has a five-year performance of %. Its 52-week range is between 0.466 and 1.7, which gives BBI stock a 52-week price range ratio of 23.82%

Brickell Biotech, Inc. currently has a PE ratio of -1.60, a price-to-book (PB) ratio of 3.04, a price-to-sale (PS) ratio of 194.49, a price to cashflow ratio of 82.40, a PEG ratio of 2.32, a ROA of -109.77%, a ROC of -148.16% and a ROE of -146.88%. The company’s profit margin is -%, its EBITDA margin is -9 427.00%, and its revenue ttm is $337.00 Thousand , which makes it $0.00 revenue per share.

Of the last four earnings reports from Brickell Biotech, Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.11 for the next earnings report. Brickell Biotech, Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Brickell Biotech, Inc. is (0), with a target price of $5, which is +557.90% compared to the current price. The earnings rating for Brickell Biotech, Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Brickell Biotech, Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Brickell Biotech, Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 25.68, ATR14 : 0.04, CCI20 : 63.00, Chaikin Money Flow : 0.27, MACD : 0.02, Money Flow Index : 74.71, ROC : 8.57, RSI : 54.39, STOCH (14,3) : 53.33, STOCH RSI : 0.00, UO : 57.60, Williams %R : -46.67), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Brickell Biotech, Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0 (0.00 %)
Moderate Buy
0
0
0 (0.00 %)
Hold
0
0
1 (100.00 %)
Moderate Sell
0
0
0 (0.00 %)
Strong Sell
0
0
0 (0.00 %)
Summary Rating--Hold
3.00

Brickell Biotech, Inc.

Brickell Biotech Inc is a United States-based clinical-stage pharmaceutical company focused on developing therapeutics for the treatment of skin diseases. Its pipeline consists of therapeutics for Hyperhidrosis, Cutaneous T-cell lymphoma, Psoriasis, and Other prevalent severe skin diseases. The company's pipeline products include Sofpironium Bromide, BBI-3000 and BBI-6000 among others.

CEO: Robert Busard Brown

Telephone: +1 720 505-4755

Address: 5777 Central Avenue, Boulder 80301, CO, US

Number of employees: 15

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

0%100%

Bearish Bullish

100%0%

Bearish Bullish

57%43%

Bearish Bullish

67%33%

News

Stocktwits